Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.

Galbally et al.

Titled “The risks of selective serotonin reuptake inhibitor use in infertile women: a review of the impact on fertility, pregnancy, neonatal health and beyond.”, a piece appearing in the January, 2013 edition of Human Reproduction by A.D. Domar and a team from Harvard Medical School provides important insight into the link between gestational

In July, 2008, a team of researchers from The Netherlands led by CW Noorlander published a study titled “Modulation of serotonin transporter function during fetal development causes dilated heart cardiomyopathy and lifelong behavioral abnormalities.” in PLoS One.  This article delves further into the link between prenatal exposure to a mother’s selective serotonin

Over the past several decades, drugs like Prozac and Zoloft have come under fire over a connection to birth defects (and host of other negative consequences related to SSRI use in pregnancy).  Recently, I came across a piece by L.E. Grzeskowiak et al. (2012) published in Journal of Clinical Psychopharmacology titled “Neonatal outcomes

Published in a 2005 edition of Reproduction, fertility, and development, an article titled “Fluoxetine during pregnancy: impact on fetal development.” by JL Morrison and a team of researchers from University of Adelaide (Australia) explored the connection between prenatal exposure to pregnancySSRI drugs and adverse birth outcomes including birth defects.

The team

Titled “Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation.”, an article by SF Lisboa and a team of researchers from State University of Londrina (Londrina, Brazil) that appeared in Pharmacology (2007) illustrates reasons to avoid Prozac use during pregnancy.  For clarity, “fluoxetine” is the chemical name

In 2009, S. Alwan and J.M. Friedman, a research duo from the University of British Columbia in Vancouver, published a study titled “Safety of selective serotonin reuptake inhibitors in pregnancy.” in CNS Drugs that provided important insight into the link between gestational exposure to selective serotonin reuptake inhibitor drugs (such as Prozac,

Today, I came across an article from the Netherlands by M.K. Bakker published in Pharmacoepidemiology and Drug Safety (August, 2010) titled “Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study.”, a piece that made great strides in elucidating the connection between prenatal exposure to Prozac (fluoxetine) and

In July 2010, a team of Lebanese published a study titled “Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?” in the medical journal Birth Defects Research reviewing a congenital malformation linked to prenatal Prozac (fluoxetine) exposure.  That team, led by C. Farra, was the first to associate goldenhar syndrome with

A study published in the September, 2004 edition of The international journal of neuropsyhopharmacology titled “A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate.” by J. Rampono et al. provides further insight into the connection between gestational exposure to selective serotonin reuptake inhibitor drugs